# Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer

> **NCT00352378** · PHASE3 · COMPLETED · sponsor: **National Cancer Center, Korea** · enrollment: 209 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine

## Key facts

- **NCT ID:** NCT00352378
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2005-10
- **Final completion:** 2006-01
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2011-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352378, "Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00352378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*